written on 25.04.2014
Tags:
,

Novartis hopes new COPD study data will draw patients from Glaxo's Advair

TAGS: ,

Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of its lung drugs has turned out positive study data that show its non-inferiority to Glaxo's top seller in COPD, and with its more convenient dosing regimen, it could prompt patients on Advair to make the switch.

Latest Report